ProhibitedBinding ruleNZOriginal is EnglishOfficial-source import checked

Gallium arsenide

New Zealand Cosmetic Products Group Standard Schedule 4, reference 1564.

Regulatory decision and full conditions

Status
Prohibited
Legal role
Binding rule
Regulatory summary
New Zealand Cosmetic Products Group Standard Schedule 4, reference 1564.
Conditions and restrictions
A prohibition entry may contain no separate condition text because the regulatory outcome is the prohibition itself. Open the cited source and apply the market-wide requirements below.

Substance identity

Official source name
Gallium arsenide
CAS
1303-00-0
EC
Not supplied in this source row
Identity mapping
standalone:official_nz_schedule

Cross-market snapshot for this identity

Exact linked records currently present in this site. An absent market means no imported exact match, not permission to use the substance.

6 market datasets
PubChem 2D chemical structure for CAS 1303-00-0
CAS 1303-00-0PubChem CID 14770

Verified chemistry for CAS 1303-00-0

Gallium arsenide

IUPAC name
gallanylidynearsane
Molecular formula
AsGa
Molecular weight
144.645 g/mol
Exact mass
143.84717 Da
Monoisotopic mass
143.84717 Da
Topological polar surface area
0.0 Ų
Molecular complexity
10.0
Formal charge
0
Hydrogen-bond donors
0
Hydrogen-bond acceptors
0
Rotatable bonds
0
Heavy atoms
2
Covalent units
1

Names and synonyms reported to PubChem

Gallium arsenide (GaAs)Gallium monoarsenideGallium monoarsenide (GaAs)GaAs27FC46GA44Gallium ArsenatumRefChem:58150215-114-8
15 more reported names
CCRIS 4020HSDB 4376EINECS 215-114-8arsinogallaneUNII-27FC46GA44GalliummonoarsenideGallium Arsenide, piecesEC 215-114-8GALLIUM ARSENIDE [MI]Gallium arsenide, pieces, 99.999% trace metals basisGallium arsenide Optical Window, 12.7mm (0.5in) dia x 1mm (0.04in) thickGallium arsenide Optical Window, 12.7mm (0.5in) dia x 2mm (0.08in) thickGallium arsenide Optical Window, 25.4mm (1.0in) dia x 2mm (0.08in) thickGallium arsenide Optical Window, 50.8mm (2.0in) dia x 2mm (0.08in) thickGallium arsenide, (single crystal substrate), <100>, diam. x thickness 2 in. x 0.5 mm
Advanced structure statistics
Defined atom stereocentres
0
Undefined atom stereocentres
0
Defined bond stereocentres
0
Undefined bond stereocentres
0
3D conformers
0
Machine-readable structure identifiers
SMILES
[Ga]#[As]
InChI
InChI=1S/As.Ga
InChIKey
JBRZTFJDHDCESZ-UHFFFAOYSA-N

Evidence from additional scientific databases

NIH PubChem PUG-View
Exact identifier match14770

Attributed physical-property, hazard, environmental and use annotations.

  • Substance: Gallium Arsenide Source: NTP Technical Reports
  • NTP Technical Report: TR-492: Toxicology and Carcinogenesis Studies of Gallium Arsenide (CASRN 1303-00-0) in F344/N Rats and B6C3F1 Mice (Inhalation Studies) (2000 ) Source: NTP Technical Reports
  • Peer Review Date: 05/21/99 Source: NTP Technical Reports
  • Conclusion for Male Rat: No Evidence Source: NTP Technical Reports
  • Conclusion for Female Rat: Clear Evidence Source: NTP Technical Reports
  • Conclusion for Male Mice: No Evidence Source: NTP Technical Reports
  • Conclusion for Female Mice: No Evidence Source: NTP Technical Reports
  • Summary: Under the conditions of these 2-year inhalation studies, there was no evidence of carcinogenic activity of gallium arsenide in male F344/N rats exposed to 0.01, 0.1, or 1.0 mg/m3. There was clear evidence of carcinogenic activity in female F344/N rats based on increased incidences of benign and malignant neoplasms in the lung. Increased incidences of benign neoplasms of the adrenal medulla and increased incidences of mononuclear cell leukemia were also considered to be exposure related. There was no evidence of carcinogenic activity in male or female B6C3F1 mice exposed to 0.1, 0.5, or 1.0 mg/m3.; Exposure to gallium arsenide caused a spectrum of nonneoplastic lesions in the lung of rats and mice, the larynx of male rats and hyperplasia of the tracheobronchial lymph node in mice. Source: NTP Technical Reports
  • Carcinogen Classification: 1, carcinogenic to humans. (L135) Source: Toxin and Toxin Target Database (T3DB)
  • First Aid: EYES: First check the victim for contact lenses and remove if present. Flush victim's eyes with water or normal saline solution for 20 to 30 minutes while simultaneously calling a hospital or poison control center. Do not put any ointments, oils, or medication in the victim's eyes without specific instructions from a physician. IMMEDIATELY transport the victim after flushing eyes to a hospital even if no symptoms (such as redness or irritation) develop.; SKIN: IMMEDIATELY flood affected skin with water while removing and isolating all contaminated clothing. Gently wash all affected skin areas thoroughly with soap and water. If symptoms such as redness or irritation develop, IMMEDIATELY call a physician and be prepared to transport the victim to a hospital for treatment.; INHALATION: IMMEDIATELY leave the contaminated area; take deep breaths of fresh air. IMMEDIATELY call a physician and be prepared to transport the victim to a hospital even if no symptoms (such as wheezing, coughing, shortness of breath, or burning in the mouth, throat, or chest) develop. Provide proper respiratory protection to rescuers entering an unknown atmosphere. Whenever possible, Self-Contained Breathing Ap Source: CAMEO Chemicals
  • Signal: Danger Source: Regulation (EC) No 1272/2008 of the European Parliament and of the Council
  • GHS Hazard Statements: H350: May cause cancer [Danger Carcinogenicity]; H360F: May damage fertility [Danger Reproductive toxicity]; H372: Causes damage to organs through prolonged or repeated exposure [Danger Specific target organ toxicity, repeated exposure] Source: Regulation (EC) No 1272/2008 of the European Parliament and of the Council
  • Precautionary Statement Codes: P203, P260, P264, P270, P280, P318, P319, P405, and P501 (click each P-code to see the statement) Source: Regulation (EC) No 1272/2008 of the European Parliament and of the Council
  • Note: This chemical does not meet GHS hazard criteria for 6.2% (7 of 112) of reports. Source: European Chemicals Agency (ECHA)
  • Signal: Danger Source: European Chemicals Agency (ECHA)
  • GHS Hazard Statements: H350 (88.4%): May cause cancer [Danger Carcinogenicity]; H360 (50.9%): May damage fertility or the unborn child [Danger Reproductive toxicity]; H372 (88.4%): Causes damage to organs through prolonged or repeated exposure [Danger Specific target organ toxicity, repeated exposure] Source: European Chemicals Agency (ECHA)
  • Precautionary Statement Codes: P203, P260, P264, P270, P280, P318, P319, P405, and P501 (click each P-code to see the statement) Source: European Chemicals Agency (ECHA)
  • ECHA C&L Notifications Summary: Aggregated GHS information provided per 112 reports by companies from 7 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.; Reported as not meeting GHS hazard criteria per 7 of 112 reports by companies.; There are 6 notifications provided by 105 of 112 reports by companies with hazard statement code(s).; Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown. For more detailed information, please visit ECHA C&L website. Source: European Chemicals Agency (ECHA)
  • Signal: Danger Source: NITE-CMC
  • GHS Hazard Statements: H350: May cause cancer [Danger Carcinogenicity]; H360: May damage fertility or the unborn child [Danger Reproductive toxicity]; H370: Causes damage to organs [Danger Specific target organ toxicity, single exposure]; H372: Causes damage to organs through prolonged or repeated exposure [Danger Specific target organ toxicity, repeated exposure] Source: NITE-CMC
  • Precautionary Statement Codes: P203, P260, P264, P270, P280, P308+P316, P318, P319, P321, P405, and P501 (click each P-code to see the statement) Source: NITE-CMC
  • Signal: Danger Source: Hazardous Chemical Information System (HCIS), Safe Work Australia
  • Health Effects: Arsenic poisoning can lead to death from multi-system organ failure, probably from necrotic cell death, not apoptosis. Arsenic is also a known carcinogen, esepcially in skin, liver, bladder and lung cancers. (T1, L20) Source: Toxin and Toxin Target Database (T3DB)
  • Toxicity Summary: Arsenic and its metabolites disrupt ATP production through several mechanisms. At the level of the citric acid cycle, arsenic inhibits pyruvate dehydrogenase and by competing with phosphate it uncouples oxidative phosphorylation, thus inhibiting energy-linked reduction of NAD+, mitochondrial respiration, and ATP synthesis. Hydrogen peroxide production is also increased, which might form reactive oxygen species and oxidative stress. Arsenic's carginogenicity is influenced by the arsenical binding of tubulin, which results in aneuploidy, polyploidy and mitotic arrests. The binding of other arsenic protein targets may also cause altered DNA repair enzyme activity, altered DNA methylation patterns and cell proliferation. (T1, A17) Source: Toxin and Toxin Target Database (T3DB)

Mapped by: Existing checksum-valid CAS to unique PubChem CID match. Retrieved: 2026-08-31. Open source record

Scientific classifications and hazard annotations provide context and do not replace the market-specific regulatory decision shown above.

Additional source coverage and match status
SourceResultChecked
NIH PubChem PUG-ViewExact match2026-08-31

A recorded no-match is useful evidence that the source was checked; it is not a claim that the substance does not exist elsewhere.

Retrieved from NIH PubChem on 2026-08-31 by checksum-valid CAS matching. Chemical properties do not replace the regulatory decision on this page.

Official source and provenance

Registered source
New Zealand cosmetic product schedules 4–8
Source reference
Schedule 4, reference 1564, source row 2049
Source record ID
S4-2049
Source version
effective-2026-01-01
Source language
English
Translation status
Original is English
Effective date
2026-01-01
Source updated
2024-01-01
Snapshot checked
2026-08-30 04:54 UTC
Validation method
openpyxl extraction; reviewed per-schedule counts
SHA-256
4e62e372fb0aad7ac630af8c41fa50b38b52a793fd51b99697a65f8ecce1ae8a

Registered dataset notes

Dataset coverage
Prohibited and restricted substances, permitted colorants, preservatives and UV filters
Authority note
Official EPA group standard schedules; current market-specific rule source

How this record fits the market dataset

2913
current New Zealand records
2166
records marked Prohibited
2913
records from this source version
2821
market records with CAS identity

Status distribution

Condition text is present on 747 of 2913 current records. An empty condition field is interpreted according to the record type above; it is never converted into an unrestricted-use claim.

New Zealand market context

Complete schedules dataset

Coverage version: Cosmetic Products Group Standard schedules effective 1 January 2026

Schedules 4–8: prohibited, restricted, colourant, preservative and UV-filter entries.

Verification checklist

  1. Search exact identity across Schedules 4–8.
  2. Apply use, concentration and warning conditions.
  3. Check hazardous-substance classification and Group Standard scope.
  4. Confirm the latest legal instrument, not only the spreadsheet.

Official market sources

Verification workflow and record completeness

Before using this result in a compliance decision

  1. Confirm that “Gallium arsenide” and every CAS/EC identifier refer to the material in your supplier specification.
  2. Search exact identity across Schedules 4–8.
  3. Apply use, concentration and warning conditions.
  4. Check hazardous-substance classification and Group Standard scope.
  5. Confirm the latest legal instrument, not only the spreadsheet.
  6. Document the source version and recheck the regulator before manufacture, notification or market placement.

Fields available in this record

  • Official substance nameAvailable
  • CASAvailable
  • ECNot supplied
  • Separate condition textNot present in source row
  • Effective dateAvailable
  • Snapshot hash and methodAvailable

Questions this page answers

This official record identifies the substance as prohibited for cosmetic use in the stated market scope. Do not rely on a formulation containing this identity until the cited source, effective date and exact substance match have been verified.

A prohibition entry may contain no separate condition text because the regulatory outcome is the prohibition itself. The searchable spreadsheet is an aid; the legal Group Standard and incorporated notices remain authoritative.

The record cites Schedule 4, reference 1564, source row 2049, source version effective-2026-01-01. Open the official source.

No. CAS helps resolve identity, but jurisdictions can classify the same substance differently and can apply different product scopes, limits, warnings and transition dates.

Stable citation

Gallium arsenide. Schedule 4, reference 1564, source row 2049. New Zealand. Source version effective-2026-01-01. CosIng Checker regulatory record: https://cosingchecker.com/regulations/nz/records/8709/

Cite the regulator as the legal authority. This page is a structured evidence index and verification aid, not a substitute for the official text or professional legal assessment.

Interpretation and limits for New Zealand

This official record identifies the substance as prohibited for cosmetic use in the stated market scope.

Do not rely on a formulation containing this identity until the cited source, effective date and exact substance match have been verified.

How to interpret the legal role

The cited row forms part of a binding rule or legally incorporated list for this market.

Evidence on this page

  • Recorded outcome: Prohibited
  • Legal role: Binding rule
  • Source version: effective-2026-01-01
  • Effective date: 2026-01-01

What it does not prove

The searchable spreadsheet is an aid; the legal Group Standard and incorporated notices remain authoritative.

Further authoritative substance research

These sources can add identity, safety, exposure or hazard context. A link is not evidence that the database contains this exact substance, and none of these sources overrides the market decision above.

Cosmetic Ingredient Review safety assessments

Expert Panel conclusions, assessed ingredient groups, use conditions, dates and report documents

Independent expert review considered by FDA; not a government approval or binding market rule

Research this identity at the source

FDA Global Substance Registration System

UNII identifiers, preferred names, substance types, codes and public substance relationships

Identity registry only; UNII availability does not imply FDA review or approval

Research this identity at the source

ILO/WHO International Chemical Safety Cards

Hazards, symptoms, first aid, storage, incompatibilities and physical properties for covered chemicals

International occupational chemical-safety reference; not cosmetic-use approval

Research this identity at the source

Japan NITE-CHRIP

Chemical identity, Japanese and foreign legal lists, GHS hazards and exposure-related information

Chemical-management evidence; cosmetic status remains governed by the applicable MHLW standard and market rules

Research this identity at the source

NIOSH Pocket Guide to Chemical Hazards

REL, PEL, IDLH, properties, exposure routes, symptoms, target organs, first aid and measurement methods for covered workplace chemicals

US occupational-health guidance and limits; not a cosmetic ingredient decision

Research this identity at the source

OECD eChemPortal

Gateway to authority-owned physical-property, fate, ecotoxicity, toxicity, exposure and GHS records

Discovery gateway; each linked authority remains responsible for its data

Research this identity at the source

US EPA CompTox CTX APIs

API key required for import

DTXSID identity, experimental and predicted properties, toxicity, bioactivity, exposure and environmental data

Scientific and computational evidence; predictions must remain labelled and do not determine cosmetic legality

Research this identity at the source